{"id":54888,"date":"2026-01-20T20:34:59","date_gmt":"2026-01-20T12:34:59","guid":{"rendered":"https:\/\/flcube.com\/?p=54888"},"modified":"2026-01-20T20:35:00","modified_gmt":"2026-01-20T12:35:00","slug":"shionogi-boosts-viiv-stake-to-21-7-in-2-1-billion-deal-doubles-down-on-hiv-focus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54888","title":{"rendered":"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus"},"content":{"rendered":"\n<p><strong>Shionogi Co., Ltd<\/strong> announced it will invest <strong>USD\u202f2.1\u202fbillion<\/strong> to increase its stake in <strong>ViiV Healthcare<\/strong> to <strong>21.7%<\/strong>, in a deal that will see <strong>Pfizer exit the joint venture<\/strong> while reinforcing Shionogi\u2019s strategic focus on <strong>HIV and infectious diseases<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shionogi Co., Ltd (Japan)<\/td><\/tr><tr><td><strong>Investment<\/strong><\/td><td>USD\u202f2.1\u202fbillion<\/td><\/tr><tr><td><strong>Target Stake<\/strong><\/td><td>21.7% in ViiV Healthcare (post\u2011transaction)<\/td><\/tr><tr><td><strong>Current JV Structure<\/strong><\/td><td>ViiV Healthcare (GSK majority, Shionogi, Pfizer)<\/td><\/tr><tr><td>**Transaction Mechanics<\/td><td>ViiV sells new shares to Shionogi; buys back shares from Pfizer (Pfizer exits)<\/td><\/tr><tr><td>**Strategic Rationale<\/td><td>Doubles down on long\u2011acting and next\u2011generation HIV treatments<\/td><\/tr><tr><td>**ViiV Significance<\/td><td>Treats <strong>24+ million people<\/strong> globally with dolutegravir\u2011containing regimens<\/td><\/tr><tr><td><strong>Global HIV Market<\/strong><\/td><td>$28\u202fbillion (2025E)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-impact\">Strategic Positioning &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Shionogi\u2019s Commitment:<\/strong> Investment signals <strong>long\u2011term bet<\/strong> on ViiV\u2019s <strong>HIV innovation pipeline<\/strong>, particularly <strong>long\u2011acting therapies<\/strong> (e.g., cabotegravir, lenacapavir)<\/li>\n\n\n\n<li><strong>Pfizer Exit:<\/strong> Allows ViiV to <strong>simplify governance<\/strong> and focus R&amp;D on core HIV assets; Shionogi gains <strong>greater strategic influence<\/strong><\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> ViiV\u2019s <strong>dolutegravir\u2011based regimens<\/strong> dominate global HIV treatment; Shionogi\u2019s increased stake aligns with <strong>growing infectious disease portfolio<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Value:<\/strong> ViiV\u2019s next\u2011gen assets include <strong>bimonthly injectables<\/strong> and <strong>broadly neutralizing antibodies<\/strong> targeting functional cure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2025E<\/th><th>2026E<\/th><th>2027E<\/th><\/tr><\/thead><tbody><tr><td>**ViiV Revenue<\/td><td>$8.5\u202fbillion<\/td><td>$9.2\u202fbillion<\/td><td>$10.0\u202fbillion<\/td><\/tr><tr><td>**Shionogi Share of Profit<\/td><td>$560\u202fmillion<\/td><td>$750\u202fmillion<\/td><td>$970\u202fmillion<\/td><\/tr><tr><td>**Shionogi R&amp;D Investment (HIV)<\/td><td>$280\u202fmillion<\/td><td>$340\u202fmillion<\/td><td>$420\u202fmillion<\/td><\/tr><tr><td>**Pfizer Exit Proceeds<\/td><td>~$1.5\u202fbillion (estimated)<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ROI Projection:<\/strong> Shionogi\u2019s investment expected to <strong>generate positive returns by 2027<\/strong> through profit share and pipeline value accretion<\/li>\n\n\n\n<li><strong>Debt Impact:<\/strong> Transaction funded via <strong>cash reserves and debt<\/strong>; maintains investment\u2011grade rating<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion, ViiV\u2019s pipeline advancement, and Shionogi\u2019s strategic returns. Actual results may differ due to regulatory changes, competitive dynamics in HIV treatment, and ViiV\u2019s clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[309,423,487],"class_list":["post-54888","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-pfizer","tag-shionogi","tag-viiv-healthcare"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare to 21.7%, in a deal that will see Pfizer exit the joint venture while reinforcing Shionogi\u2019s strategic focus on HIV and infectious diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54888\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus\" \/>\n<meta property=\"og:description\" content=\"Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare to 21.7%, in a deal that will see Pfizer exit the joint venture while reinforcing Shionogi\u2019s strategic focus on HIV and infectious diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54888\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T12:34:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T12:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54888#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54888\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus\",\"datePublished\":\"2026-01-20T12:34:59+00:00\",\"dateModified\":\"2026-01-20T12:35:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54888\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Pfizer\",\"Shionogi\",\"ViiV Healthcare\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54888#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54888\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54888\",\"name\":\"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-20T12:34:59+00:00\",\"dateModified\":\"2026-01-20T12:35:00+00:00\",\"description\":\"Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare to 21.7%, in a deal that will see Pfizer exit the joint venture while reinforcing Shionogi\u2019s strategic focus on HIV and infectious diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54888#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54888\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54888#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare to 21.7%, in a deal that will see Pfizer exit the joint venture while reinforcing Shionogi\u2019s strategic focus on HIV and infectious diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54888","og_locale":"en_US","og_type":"article","og_title":"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus","og_description":"Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare to 21.7%, in a deal that will see Pfizer exit the joint venture while reinforcing Shionogi\u2019s strategic focus on HIV and infectious diseases.","og_url":"https:\/\/flcube.com\/?p=54888","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-20T12:34:59+00:00","article_modified_time":"2026-01-20T12:35:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54888#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54888"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus","datePublished":"2026-01-20T12:34:59+00:00","dateModified":"2026-01-20T12:35:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54888"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Pfizer","Shionogi","ViiV Healthcare"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54888#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54888","url":"https:\/\/flcube.com\/?p=54888","name":"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-20T12:34:59+00:00","dateModified":"2026-01-20T12:35:00+00:00","description":"Shionogi Co., Ltd announced it will invest USD\u202f2.1\u202fbillion to increase its stake in ViiV Healthcare to 21.7%, in a deal that will see Pfizer exit the joint venture while reinforcing Shionogi\u2019s strategic focus on HIV and infectious diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54888#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54888"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54888#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi Boosts ViiV Stake to 21.7% in $2.1\u202fBillion Deal, Doubles Down on HIV Focus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54888"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54888\/revisions"}],"predecessor-version":[{"id":54890,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54888\/revisions\/54890"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}